Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG48WN)

• Drug Name: G0-203-2c Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 1/2	[1]
Acute myeloid leukaemia	2A60	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DMG48WN

Molecule-Related Drug Atlas

Drug(s) Targeting Mucin-1 (MUC1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Yttrium (90Y) clivatuzumab tetraxetan	DMOLR5W	Pancreatic cancer	2C10	Phase 3	[4]
TG-4010	DMWE3GB	Bipolar disorder	6A60	Phase 2/3	[5]
ICO-25	DMC13BQ	Breast cancer	2C60-2C65	Phase 2	[6]
MUC1-Poly-ICLC	DML7N4B	Colorectal cancer	2B91.Z	Phase 2	[7]
AS-1402	DMMX1EJ	Breast cancer	2C60-2C65	Phase 2	[8]
Emepepimut-S	DMCLT2F	Non-small-cell lung cancer	2C25.Y	Phase 2	[9]
GO-203-2c	DMLWKZ7	Acute myeloid leukaemia	2A60	Phase 2	[3]
SAR-566658	DMT4FI5	Triple negative breast cancer	2C60-2C65	Phase 2	[10]
Pankomab-GEX	DMAZ460	Solid tumour/cancer	2A00-2F9Z	Phase 2	[11]
ImMucin	DM09JOZ	Multiple myeloma	2A83	Phase 1/2	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Mucin-1 (MUC1)	TTBHFYQ	MUC1_HUMAN	Modulator	[3]

References

• [1] ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Genus 0ncology.
• [3] Clinical pipeline report, company report or official report of Genus Oncology.
• [4] Clinical pipeline report, company report or official report of Immunomedics.
• [5] A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol. 2008 Jul;3(7):735-44.
• [6] The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5.
• [7] Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments. Oncoimmunology. 2013 Mar 1;2(3):e23429.
• [8] Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res. 2009;11(5):R73.
• [9] Emepepimut-S for non-small cell lung cancer. Expert Opin Biol Ther. 2011 Aug;11(8):1091-7.
• [10] Integrating in vitro signaling and drug response data from single cell network profiling (SCNP) to inform on individual's AML biology.Molecular Cancer Therapeutics. 11/2011; 10(Supplement 1):A73-A73.
• [11] Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8. Histol Histopathol. 2013 Feb;28(2):239-44.
• [12] Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients. Br J Haematol. 2015 Apr;169(1):44-56.